March 26 (Reuters) - Protagonist Therapeutics Inc:
* PROTAGONIST THERAPEUTICS DISCONTINUES PHASE 2B PROPEL TRIAL OF PTG-100 FOR THE TREATMENT OF ULCERATIVE COLITIS FOLLOWING INTERIM ANALYSIS
* PROTAGONIST THERAPEUTICS - USING PRE-SPECIFIED CRITERIA, DMC DEEMED TRIAL TO BE FUTILE BASED ON AN ANALYSIS OF PRIMARY ENDPOINT OF CLINICAL REMISSION
* PROTAGONIST THERAPEUTICS INC - NO SAFETY CONCERNS WERE NOTED IN ANALYSIS
* PROTAGONIST THERAPEUTICS INC - DECISION FOLLOWED A PLANNED INTERIM ANALYSIS BY AN INDEPENDENT DATA MONITORING COMMITTEE
* PROTAGONIST THERAPEUTICS- TO POSTPONE DECISION ABOUT INITIATION OF PHASE 2/3 CLINICAL TRIAL OF PTG-100 IN CHRONIC POUCHITIS
* PROTAGONIST THERAPEUTICS- TO POSTPONE DECISION ABOUT INITIATION OF PHASE 2/3 CLINICAL UNTIL AFTER FULL REVIEW OF INTERIM DATA FROM UC PROPEL STUDY Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)